We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Immune Design Corp. (NASDAQGM: IMDZ) to Merck & Co., Inc. (NYSE: MRK). Under the terms of the transaction, Immune Design shareholders will receive $5.85 for each share of Immune Design stock they own.
The Immune Design merger investigation concerns whether the Board of Immune Design breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Merck is underpaying for Immune Design shares, thus unlawfully harming Immune Design shareholders.
To receive more information, please fill out the form.